MacroGenics Plans To Present Dose Escalation And Preliminary Tumor-Specific Cohort Results At The European Society For Medical Oncology Congress, October 23-27

Chronic Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsight

The chronic myeloid leukemia (CML) clinical trial pipeline shows robust activity with 25+ pharmaceutical companies developing 25+ pipeline drugs. Key players including Merck, Enliven Therapeutics, ImmunoForge, and others are advancing promising therapies like TERN-701, ELVN-001, and KF1601 across various clinical stages. The market is evolving from established tyrosine kinase inhibitors toward newer selective agents targeting resistance, intolerance, and treatment-free remission.

B. Riley Securities Maintains Buy on Macrogenics, Raises Price Target to $11

B. Riley Securities analyst Mayank Mamtani maintains Macrogenics (NASDAQ:MGNX) with a Buy and raises the price target from $9 to $11.

UPDATE: Macrogenics Q2 Adj. EPS $(0.27) Misses $(0.13) Estimate, Sales $32.832M Miss $67.456M Estimate

Macrogenics (NASDAQ:MGNX) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.13) by 107.69 percent. This is a 52.63 percent increase over losses of $(0.57) per share from

Macrogenics Q2 EPS $(0.31) Misses $0.02 Estimate, Sales $32.832M Miss $67.456M Estimate